Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30270468 | 1.00 | ALDH1A1 (0.64) | ALDH1A1LMNAGAASMN1; SMN2CYP19A1 | |
| SCHEMBL6290158 | 0.85 | ALDH1A1 (0.66) | ALDH1A1LMNAGAASMN1; SMN2CYP19A1 | |
| SCHEMBL25759592 | 0.83 | ALDH1A1 (0.64) | ALDH1A1LMNAGAASMN1; SMN2CYP19A1 | |
| SCHEMBL30390015 | 0.83 | ALDH1A1 (0.64) | ALDH1A1LMNAGAASMN1; SMN2CYP19A1 | |
| SCHEMBL6370836 | 0.83 | ALDH1A1 (0.64) | ALDH1A1LMNAGAASMN1; SMN2CYP19A1 | |
| SCHEMBL3687222 | 0.83 | ALDH1A1 (0.65) | ALDH1A1LMNAGAASMN1; SMN2CYP19A1 | |
| SCHEMBL16053212 | 0.83 | ALDH1A1 (0.67) | ALDH1A1LMNAGAASMN1; SMN2CYP19A1 | |
| SCHEMBL6008517 | 0.83 | ALDH1A1 (0.64) | ALDH1A1LMNAGAASMN1; SMN2CYP19A1 | |
| SCHEMBL24370577 | 0.82 | ALDH1A1 (0.56) | ALDH1A1LMNAGAASMN1; SMN2CYP19A1 | |
| SCHEMBL3685286 | 0.81 | ALDH1A1 (0.68) | ALDH1A1LMNAGAASMN1; SMN2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| CN-115843271-A | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2023-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | ALDH1A1 995/4885LMNA 3774/4885GAA 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.